Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer암 환자에서 1차 시리즈 및 부스터 SARS-CoV-2 백신에 따른 SARS-CoV-2 바이러스 변이체의 중화 폭Comparative Study Published on 2022-01-102022-09-11 Journal: Cancer cell [Category] 변종, 진단, [키워드] Ad26 Ad26.COV2.S age Alpha Anti-spike antibody Antibody titer Beta BNT162b2 booster booster dose booster doses breadth Cancer Concentration COV2.S followed by greater magnitude immune response immune responses immunogenic increase mRNA1273 neutralization Patient Patients with cancer Positive predictive value Predictive value Protein responses against SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2 vaccines SARS-CoV-2 variant SARS-CoV-2 variants SARS-CoV-2 viral single booster dose subset These data Tumor vaccination Vaccine variant variants variety Viral viral variant wildtype [DOI] 10.1016/j.ccell.2021.12.002 PMC 바로가기 [Article Type] Comparative Study
Assessing the risk of vaccine-driven virulence evolution in SARS-CoV-2Organismal and Evolutionary Biology Published on 2022-01-052022-10-28 Journal: Royal Society Open Science [Category] COVID-19, [키워드] Alter Assessing booster doses COVID-19 COVID-19 vaccine disease disease severity Effect Efficacy Evidence Evolution Evolution of SARS-CoV-2 exacerbate Immunity immunized increases in indicate individual Infection outcome Population provide risk robust SARS-CoV-2 SARS-CoV-2 biology sustained Transmission unlikely vaccinal vaccination rate vaccination rates Vaccine virulence virulence evolution [DOI] 10.1098/rsos.211021 PMC 바로가기 [Article Type] Organismal and Evolutionary Biology
Inactivated COVID-19 Vaccine Induces a Low Humoral Immune Response in a Subset of Dermatological Patients Receiving ImmunosuppressantsMedicine Published on 2021-12-082022-10-31 Journal: Frontiers in Medicine [Category] COVID-19, [키워드] acute respiratory syndrome anti-SARS-CoV-2 IgG antibody autoimmune conditions autoimmune skin diseases Beijing benefit booster doses calculated Cancer case-control study condition CoronaVac coronavirus coronavirus disease COVID-19 COVID-19 infection greater humoral immune response IgG IgG antibody Immune-mediated immunogenicity Immunosuppressant Immunosuppressed Immunosuppression immunosuppressive therapies immunosuppressive therapy Inactivated COVID-19 vaccine Infection lack methotrexate neutralizing antibody participant Patient patients patients with HIV percentage positive Prednisolone receiving reduction respond poorly response SARS-CoV-2 seroconversion rate serum Sinovac Sinovac Life Sciences statistical significance study participant subject subset the vaccine therapy vaccination Vaccine vaccine dose were used [DOI] 10.3389/fmed.2021.769845 PMC 바로가기 [Article Type] Medicine
Are COVID-19 Vaccine Boosters Needed? The Science behind BoostersCOVID-19 백신 부스터가 필요합니까? 부스터의 과학Review Published on 2021-11-242022-09-10 Journal: Journal of Virology [Category] COVID19(2023년), MERS, SARS, 변종, [키워드] booster doses breakthrough infections COVID-19 COVID-19 vaccine distribution dose eligibility Epidemiology global pandemic herd immunity Immunity immunology Increases increases in neutralizing antibody reported Safe SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants Science the timing trajectory Vaccine Vaccine-induced immunity Vaccines [DOI] 10.1128/jvi.01973-21 PMC 바로가기 [Article Type] Review
Willingness to Receive the Booster COVID-19 Vaccine Dose in PolandArticle Published on 2021-11-052022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] Ad26.COV2.S administer AZD1222 B.1.617.2 booster booster dose booster doses Breakthrough infection Chronic diseases conducted COVID-19 COVID-19 vaccination COVID-19 vaccine cross-sectional decrease dose doses effective Evolution Factor Frequency group identify Immunosuppressed individual infections Influenza lowest majority median mitigate mRNA vaccine mRNA vaccines obesity Older pandemic participant Poland POLE pre-vaccination Prevent receive receiving risk SARS-CoV-2 SARS-CoV-2 infections serum antibody severe SARS-CoV-2 severity Side effect significantly more subject transmissible variants vaccinated individual vaccination Vaccine Vaccine hesitancy vector vaccines virus spread was increased [DOI] 10.3390/vaccines9111286 PMC 바로가기 [Article Type] Article
Neutralizing antibody responses following natural SARS-CoV-2 infection: Dynamics and correlation with commercial serologic tests자연적인 SARS-CoV-2 감염에 따른 중화 항체 반응: 상업적 혈청학적 검사와의 역학 및 상관관계Article Published on 2021-11-012022-09-11 Journal: Journal of Clinical Virology [Category] MERS, SARS, 진단, 치료기술, 치료법, [키워드] allocation anti-SARS-CoV-2 Anti-spike Antibody Response Antibody titer Antibody titers assays booster doses correlation COVID-19 cross-reactivity demonstrated detect diagnostic domain Dynamics Efficacy Elecsy Elecsys ELISA Euroimmun evaluate evaluated except for facilitate Follow-up healthcare worker IgG immunoassay immunoassays long term MONITOR NAbs Neutralizing antibodies Neutralizing antibody response neutralizing capacity participant participated performed plaque reduction neutralization Post-vaccine Protein reference standard SARS-CoV-2 SARS-CoV-2 IgG SARS-CoV-2 immunity SARS-COV-2 infection SARS-CoV-2 neutralizing antibodies sera serologic test serologic tests seronegative seroprevalence survey significant decrease Support the immunoassay total antibodies vaccination [DOI] 10.1016/j.jcv.2021.104988 PMC 바로가기 [Article Type] Article
Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis건강한 성인의 SARS-COV-2 변이체 mRNA 백신 부스터의 안전성 및 면역 원성 : 중간 분석Clinical Trial Published on 2021-09-152022-08-13 Journal: Nature Medicine [Category] MERS, SARS, 변종, 임상, 진단, [키워드] (Beta) addition assessment assessments B.1.351 B.1.617.2 Beta boost booster booster dose booster doses clinical COVID-19 vaccine COVID-19 vaccine mRNA-1273 Delta dose evaluate Exploratory analyses Exploratory analysis exploratory interim analysis Gamma group healthy immunogenicity include interim analysis mRNA mRNA vaccine mRNA-1273 mRNA-1273 booster mRNA-1273.211 multivalent mRNA-1273.211 neutralization neutralization titer neutralization titers Neutralizing antibodies neutralizing antibody Open-label open-label phase 2a study P.1 RNA vaccines Safe Safety SARS-CoV-2 variant SARS-CoV-2 variants significant increase single booster dose statistically susceptibility titers Trial trial participant undetectable Vaccine variant variant-modified booster variant-modified boosters variant-modified mRNAs variant-specific vaccines variants variants of interest VoC VOCs VOIs waned wild-type D614G wild-type D614G virus [DOI] 10.1038/s41591-021-01527-y PMC 바로가기 [Article Type] Clinical Trial
Prioritizing ‘equity’ in COVID-19 vaccine distribution through Global Health DiplomacyPerspective Published on 2021-08-182022-10-31 Journal: Health Promotion Perspectives [Category] COVID-19, [키워드] accelerate addressed Against booster doses China Consequences coronavirus disease country Coverage COVID-19 COVID-19 vaccine Critical death distribution dose effort equity FIVE global health global health security Health health diplomacy Healthcare system initial International majority mechanism medication pandemic Pandemics reached Russia social determinants The United States the vaccine Treatment United Kingdom vaccination Vaccine Vaccines [DOI] 10.34172/hpp.2021.36 PMC 바로가기 [Article Type] Perspective
COVID-19 Vaccines Safety Tracking (CoVaST): Protocol of a Multi-Center Prospective Cohort Study for Active Surveillance of COVID-19 Vaccines’ Side EffectsStudy Protocol Published on 2021-07-252022-10-29 Journal: International Journal of Environmental Research an [Category] COVID-19, SARS, [키워드] booster booster doses Cohort studies COVID-19 COVID-19 vaccine Cross-sectional studies cross-sectional survey disease drug-related side effects and adverse reactions Effect Effectiveness groups Health personnel independent investigated mass vaccination MONITOR Prevalence Prospective questionnaire Registered Safety side Side effect Side effects Study protocol vaccination Vaccines [DOI] 10.3390/ijerph18157859 PMC 바로가기 [Article Type] Study Protocol
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial우려되는 SARS-CoV-2 변이체에 대한 ChAdOx1 nCoV-19(AZD1222) 백신의 효능 202012/01(B.1.1.7): 무작위 대조 시험의 탐색적 분석Clinical Trial Published on 2021-04-102022-08-13 Journal: Lancet (London, England) [Category] MERS, SARS, 변종, 임상, 진단, [키워드] 1:1 95% CI adenoviral vector vaccine Ageusia analysed Anosmia assigned AstraZeneca AZD1222 B.1.1.7 B.1.1.7 lineage B.1.1.7 variant booster dose booster doses calculated canonical ChAdOx1 ChAdOx1 nCoV-19 Clinical research Clinical vaccine efficacy Coalition collected cough COVID-19 COVID-19 disease disease dominant Efficacy efficacy analysis efficacy cohort enrolled Exploratory analysis female Fever finding funding Genomics geometric mean geometric mean ratio groups in vitro Infection Innovation ISRCTN Lineage lineages MenACWY microneutralisation assay NAAT NAAT positive NAAT positive swab network neutralisation activity neutralising antibody response Neutralising antibody responses NIHR NIHR Oxford Biomedical Research Centre non-B.1.1.7 variant nose and throat nucleic acid nucleic acid amplification nucleic acid amplification test Oxford participant phase 2/3 Poisson regression model positive sample post-hoc analysis provided randomised controlled trial Randomly receive recruited reduced Registered Relative risk risk robust SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variant second dose second dose of vaccine sequenced seronegative participant seronegative participants Shortness of breath South Swab swabs symptomatic symptomatic COVID-19 symptoms of COVID-19 tested the vaccine throat swabs Trial upper airway upper airway swab Vaccine vaccine efficacy vaccine-induced antibodies vaccine-induced antibody Valley variant variant of SARS-CoV-2 Victoria Victoria lineage virus neutralisation activity were measured [DOI] 10.1016/S0140-6736(21)00628-0 PMC 바로가기 [Article Type] Clinical Trial